Page 1

Иvalneva VALNEVA SE Campus Bio - Ouest | 6 , Rue Alain Bombard 44800 Saint - Herblain , France Valneva Reports H1 2021 Financial Results and Provides Business Update Key R & D Milestones Achieved • • • Positive topline Phase 3 results for single - shot chikungunya vaccine candidate VLA1553 ○ Protective neutralizing antibodies induced in 98.5 % of trial participants Recruitment completed for Phase 2 trial VLA15-221 of Lyme disease vaccine candidate including pediatric age group Recruitment completed for pivotal Phase 3 trial of inactivated , adjuvanted COVID - 19 vaccine candidate VLA2001 о Phase 3 topline data now expected early in fourth quarter 2021 Strong financial position $ 107.6 million of gross proceeds raised in a US initial public offering and a concurrent private placement in Europe • Cash and cash equivalents of € 329.8 million at June 30 , 2021 2021 financial guidance ( excluding COVID ) reconfirmed . • Total revenues , excluding VLA2001 , of € 80 million to € 105 million R & D expenses , excluding VLA2001 , of € 65 million to € 75 million Thomas Lingelbach , Valneva's Chief Executive Officer , commented , " Valneva is continuing to hit its major R & D objectives . We have just reported great results in the world's first ever Phase 3 trial for a chikungunya vaccine alongside excellent progress for our unique COVID and Lyme disease programs . Our successful Nasdaq listing marked a significant strategic step for Valneva as we look to continue to build our Company . Our team has delivered phenomenally well this year already and I would like to thank them for their continued commitment and dedication . " Financial Information ( unaudited results , consolidated under IFRS ) € in million 6 months ending June 30 2021 2020 Total revenues 47.5 47.9 Product sales 31.8 40.9 Net profit / ( loss ) ( 86.4 ) ( 25.6 ) EBITDA ( 80.1 ) ( 17.2 ) Cash ( at end of period ) 329.8 200.0 August 10 , 2021 VALNEVA SE